COVID-19 and the pharma industry.

It’s a contentious relationship, but we all have our socially responsible part to play.

We’ve all been affected by the coronavirus pandemic, and while markets are down and social distancing is the new normal, the world looks to science to find a solution.

By partnering with a global #pharma company working towards the common antivirus goal, it’s possible to achieve great things, including:

★ Performing bioanalytical testing of blood samples from COVID-19 positive patients in record time

★ Implementing, developing & validating analytical methods for the testing of raw materials in readiness for mass-producing a COVID-19 vaccine on never-before-seen scale

★ Conducting bioequivalence studies with novel neuroprotective drugs which show significant anti-inflammatory properties

QUINTA-ANALYTICA have been quietly but successfully playing their part by utilizing specialist skill sets and equipment in-house to assist multiple partners in their quest to find a vaccine, or source APIs that have become as scarce as feathers on a fish!

Working with key research projects Quinta are proud to be doing their part in the collective effort to rid the world of the most impactful issue ever seen.

Additional News

  • 3 September 2026

    Quinta-Analytica Expands HPLC Fleet to Strengthen Flexibility and Capacity for Clients

    New Thermo Scientific Vanquish Core joins an HPLC fleet of around 50 systems

  • 7 August 2026

    Quinta-Analytica at CPHI Milan 2026 – Meet Us at Conscio Group Stand 6N25

    Meet Quinta-Analytica at CPHI Milan 2026 as part of the Conscio Group team at Stand 6N25. Discuss your clinical, bioanalytical and analytical projects with our experts and arrange a meeting in advance.

  • 15 July 2026

    Quinta-Analytica Awarded the EcoVadis Gold Medal

    Quinta-Analytica has been awarded the EcoVadis Gold Medal after achieving an overall sustainability score of 84 out of 100. The result represents a substantial increase from 68 points in the previous assessment and places the company in the 97th percentile globally.